P Astoul

Summary

Country: France

Publications

  1. ncbi Pleural mesothelioma
    P Astoul
    Department of Pulmonology, Hopital de la Conception, Marseille, France
    Curr Opin Pulm Med 5:259-68. 1999
  2. ncbi Diagnostic and therapeutic thoracoscopy: techniques and indications in pulmonary medicine
    C Boutin
    Service de Pneumologie, Hopital de la Conception, Marseille, France
    Tuber Lung Dis 74:225-39. 1993
  3. ncbi [Diagnostic and therapeutic thoracoscopy]
    P Astoul
    Service de Pneumologie, Hopital de la Conception, Marseille
    Rev Prat 47:1308-14. 1997
  4. ncbi Diagnostic thoracoscopy
    C Boutin
    Department of Pulmonology, Hopital de la Conception, Marseille, France
    Clin Chest Med 19:295-309. 1998
  5. ncbi Feasibility of short term drainage for diagnostic thoracoscopy
    D P Breen
    Faculty of Medicine, Universite de la Mediterranee, Assistance Publique Hopitaux de Marseille, Department of Pulmonary Diseases, Division of Thoracic Oncology, Hopital Sainte Marguerite, Marseille, France
    Monaldi Arch Chest Dis 71:54-8. 2009
  6. ncbi [Role of DNA microarrays in the diagnosis of pleural exudates: a feasibility study]
    L Greillier
    Faculte de Medecine, Universite de la Mediterranee, Assistance Publique Hopitaux de Marseille, Service d Oncologie Thoracique, Pôle thorax, Hopital Sainte Marguerite, Marseille, France
    Rev Mal Respir 24:859-67. 2007
  7. ncbi [Validation of the French version of the Princess Margaret Hospital Patient Satisfaction with their Doctor Questionnaire]
    F Barlesi
    Service d Oncologie Thoracique, Fédération des Maladies Respiratoires, Hopital Sainte Marguerite, Faculté de Médecine Université de la Méditerranée, Marseille, France
    Rev Mal Respir 23:227-36. 2006
  8. doi Malignant pleural mesothelioma: from the bench to the bedside
    P Astoul
    Department of Thoracic Oncology, Pleural Diseases and Interventional Pulmonology, Hopital Nord, Marseille, France
    Respiration 83:481-93. 2012
  9. ncbi [Pleural mesothelioma: impact of the staging for the therapeutic strategy]
    L Greillier
    Departement des Maladies Respiratoires, Unité d Oncologie Thoracique, Hopital Sainte Marguerite, Marseille, France
    Rev Mal Respir 24:6S146-56. 2007
  10. ncbi [Severe cutaneous toxicity after Pemetrexed as second line treatment for a refractory non small cell lung cancer]
    C Tummino
    Faculte de Medecine, Université de la Méditerranée Assistance Publique Hôpitaux de Marseille, Service d Oncologie Thoracique, Hopital Sainte Marguerite, Marseille, France
    Rev Mal Respir 24:635-8. 2007

Collaborators

Detail Information

Publications37

  1. ncbi Pleural mesothelioma
    P Astoul
    Department of Pulmonology, Hopital de la Conception, Marseille, France
    Curr Opin Pulm Med 5:259-68. 1999
    ..To reach this target, all patients must be enrolled in protocols. The usual pessimism for the management of patients with malignant pleural mesothelioma is over...
  2. ncbi Diagnostic and therapeutic thoracoscopy: techniques and indications in pulmonary medicine
    C Boutin
    Service de Pneumologie, Hopital de la Conception, Marseille, France
    Tuber Lung Dis 74:225-39. 1993
    ..Recently thoracoscopy has been used with increasing frequency for the diagnosis and treatment of pleuropulmonary diseases...
  3. ncbi [Diagnostic and therapeutic thoracoscopy]
    P Astoul
    Service de Pneumologie, Hopital de la Conception, Marseille
    Rev Prat 47:1308-14. 1997
    ..In diffuse pulmonary diseases, thoracoscopy also allows lung biopsy. Some therapeutic measures are mainly feasible by this route. Pleurodesis is performed in case of recurrent pleural effusion of for pneumothorax...
  4. ncbi Diagnostic thoracoscopy
    C Boutin
    Department of Pulmonology, Hopital de la Conception, Marseille, France
    Clin Chest Med 19:295-309. 1998
    ..This article focuses on the technique, indications, and results of medical thoracoscopy...
  5. ncbi Feasibility of short term drainage for diagnostic thoracoscopy
    D P Breen
    Faculty of Medicine, Universite de la Mediterranee, Assistance Publique Hopitaux de Marseille, Department of Pulmonary Diseases, Division of Thoracic Oncology, Hopital Sainte Marguerite, Marseille, France
    Monaldi Arch Chest Dis 71:54-8. 2009
    ..Our aim was to retrospectively study all cases of diagnostic thoracoscopy and to ascertain the time of chest drain removal, length of hospital stay and associated complications...
  6. ncbi [Role of DNA microarrays in the diagnosis of pleural exudates: a feasibility study]
    L Greillier
    Faculte de Medecine, Universite de la Mediterranee, Assistance Publique Hopitaux de Marseille, Service d Oncologie Thoracique, Pôle thorax, Hopital Sainte Marguerite, Marseille, France
    Rev Mal Respir 24:859-67. 2007
    ..The aim of this study was to determine the feasibility and the diagnostic contribution of genomic analysis of cells contained in pleural fluid, using DNA microarray techniques...
  7. ncbi [Validation of the French version of the Princess Margaret Hospital Patient Satisfaction with their Doctor Questionnaire]
    F Barlesi
    Service d Oncologie Thoracique, Fédération des Maladies Respiratoires, Hopital Sainte Marguerite, Faculté de Médecine Université de la Méditerranée, Marseille, France
    Rev Mal Respir 23:227-36. 2006
    ..Outpatients' satisfaction with their doctor is a major component of total patient satisfaction. However, a validated instrument for assessing this has not previously been available in French...
  8. doi Malignant pleural mesothelioma: from the bench to the bedside
    P Astoul
    Department of Thoracic Oncology, Pleural Diseases and Interventional Pulmonology, Hopital Nord, Marseille, France
    Respiration 83:481-93. 2012
    ..Thus, this review is an overview of the recent advances in the biology of MPM and their potential therapeutic applications in the field of MPM diagnosis and treatment...
  9. ncbi [Pleural mesothelioma: impact of the staging for the therapeutic strategy]
    L Greillier
    Departement des Maladies Respiratoires, Unité d Oncologie Thoracique, Hopital Sainte Marguerite, Marseille, France
    Rev Mal Respir 24:6S146-56. 2007
    ..However, the most important point is the multidisciplinary concertation induced by the management of this disease which represents a "model" in thoracic oncology...
  10. ncbi [Severe cutaneous toxicity after Pemetrexed as second line treatment for a refractory non small cell lung cancer]
    C Tummino
    Faculte de Medecine, Université de la Méditerranée Assistance Publique Hôpitaux de Marseille, Service d Oncologie Thoracique, Hopital Sainte Marguerite, Marseille, France
    Rev Mal Respir 24:635-8. 2007
    ..However, cutaneous toxicity has been described, principally as a rash. Cutaneous toxicity of all grades has been observed in up to 14%, and grade 3 or 4 toxicity in 0.8-1.3% of cases...
  11. ncbi [Clinical types of thoracic cancer. Pleural mesothelioma]
    P Astoul
    Departement des Maladies Respiratoires, Unité d Oncologie Thoracique, Hopital Sainte Marguerite, Marseille, France
    Rev Mal Respir 23:16S177-16S187. 2006
    ....
  12. ncbi [Listening to the patient]
    P Astoul
    Fédération des Maladies Respiratoires, Unité d Oncologie Thoracique, Hopital Sainte Marguerite, Marseille, France
    Rev Mal Respir 23:10S27-10S30. 2006
  13. doi Temporary endobronchial embolization with silicone spigots for moderate hemoptysis: a retrospective study
    O Bylicki
    Department of Thoracic Oncology, Pleural Diseases and Interventional Pulmonology, Hopital Nord, University of the Mediterranean, Marseille, France
    Respiration 84:225-30. 2012
    ..When the bleeding arises from peripheral lesions that are not visible endoscopically, bronchoscopic options have limited curative intents. Endobronchial embolization using silicone spigots (EESS) is a novel approach...
  14. ncbi [Chronic atrophic polychondritis. Clinical polymorphism and severity of respiratory lesions]
    P Astoul
    Service de Pneumologie, Hopital de la Conception, Marseille
    Rev Mal Respir 10:251-4. 1993
    ..Either general or local treatment is virtually non-existent and the prognosis of these extensive respiratory forms of the disease is very poor...
  15. ncbi [Mucoepidermoid bronchial tumor with an unusual radiologic presentation]
    C Pinet
    Service de Pneumologie, Hopital de la Conception, Marseille
    Rev Mal Respir 16:379-81. 1999
    ..The prognosis is much better for tumors of low-grade malignancy and current treatment is surgical in the absence of recurrence after isolated endoscopic treatment...
  16. ncbi [Acute respiratory distress syndrome following inhalation of barium sulfate]
    Y Gernez
    Service de Reanimation Medicale, Hopital Sainte Marguerite, Faculte de Medecine, Universite de la Mediterranee, Assistance Publique Hopitaux de Marseille, Marseille, France
    Rev Mal Respir 22:477-80. 2005
    ..Barium sulfate (BS) is chosen to explore swallowing disorders because of its reduced osmolality allowing no adverse reaction if aspirated in the bronchial tree...
  17. ncbi [2000 classification of idiopathic interstitial lung diseases]
    S Boniface
    UPRES EA 3287, Departement des Maladies Respiratoires, Universite de la Mediterranee, Hopital Sainte Marguerite, Marseille, France
    Rev Med Interne 25:891-905. 2004
    ..This led the American Thoracic Society and the European Respiratory Society to propose a new classification of these diseases, in the aim to facilitate early diagnosis and specific care...
  18. ncbi [Standards, options and recommendations for the management of locally advanced non small cell lung carcinoma]
    E Bardet
    Standards, Options, Recommandations, 101, rue de Tolbiac, 75654 Paris Cedex 13
    Bull Cancer 88:369-87. 2001
    ..Surgery is justified in stage N2 disease as good local control can be achieved. T4-N0 disease should be treated surgically with curative intent...
  19. ncbi [Standards, Options and Recommendations for the management of stage I or II primary bronchial cancers treated exclusively with radiotherapy]
    E Touboul
    , Paris, France
    Cancer Radiother 5:452-63. 2001
    ....
  20. ncbi [Phase III randomised trial of adjuvant chemotherapy with cisplatin plus docetaxel versus cisplatin plus gemcitabine in resected non-small cell bronchial carcinoma with quality of life as the primary objective]
    F Barlesi
    Faculté de Médecine Université de la Méditerranée, Assistance Publique Hopitaux de Marseille, Service d Oncologie Thoracique, Fédération des Maladies Respiratoires, France
    Rev Mal Respir 23:489-96. 2006
    ..Adjuvant chemotherapy improves survival of completely resected non-small cell lung cancer (NSCLC). However the regimen of choice is not yet defined...
  21. ncbi [Cutaneous metastasis of pleural mesothelioma: two cases]
    C Gaudy-Marqueste
    Service de dermato vénéréologie, Hopital Ste Marguerite, Marseille
    Ann Dermatol Venereol 130:455-9. 2003
    ..Cutaneous manifestations of pleural mesothelioma are rare, polymorphic, and occur at various stages of the disease...
  22. ncbi [Malignant mesothelioma of the pleura: place of surgery]
    R Giudicelli
    Hopital de la Timone, Hopital Sainte Marguerite, Marseille
    Rev Mal Respir 23:10S106-10S109. 2006
  23. pmc The French National Mesothelioma Surveillance Program
    M Goldberg
    Département Santé Travail, Institut de Veille Sanitaire, 12, rue du Val d Osne, 94410 Saint Maurice, France
    Occup Environ Med 63:390-5. 2006
    ....
  24. pmc CYFRA 21-1 level predicts survival in non-small-cell lung cancer patients receiving gefitinib as third-line therapy
    F Barlesi
    Department of Thoracic Oncology, Faculty of Medicine, Assistance Publique Hopitaux de Marseille, Fédération des Maladies Respiratoires, Hopital Sainte Marguerite, 270, Bd de Sainte Marguerite, 13274 Marseille Cedex 09, France
    Br J Cancer 92:13-4. 2005
    ..In case of a CYFRA 21-1 level higher than 3.5 ng ml(-1), treatment with gefitinib needs further evaluation giving its relative poor effect on survival...
  25. pmc Positive thyroid transcription factor 1 staining strongly correlates with survival of patients with adenocarcinoma of the lung
    F Barlesi
    Faculty of Medicine Assistance Publique Hôpitaux de Marseille, Department of Thoracic Oncology, Fédération des Maladies Respiratoires, Hopital Sainte Marguerite, Marseille, France
    Br J Cancer 93:450-2. 2005
    ..30-0.85; P = 0.01) and higher grade of differentiation (HR = 0.40, 95% CI 0.24-0.68; P = 0.001). In conclusion, positive TTF1 staining strongly and independently correlates with survival of patients with primary ADC of the lung...
  26. pmc Summary report of the Standards, Options and Recommendations for the management of patients with non-small-cell lung carcinoma (2000)
    A Depierre
    Hopital Jean Minjoz, Besancon, France
    Br J Cancer 89:S35-49. 2003
  27. ncbi [Bronchoscopy in the diagnosis of lung cancer: an evaluation of current practice]
    F Barlesi
    Service d Oncologie Thoracique, Fédération des Maladies Respiratoires, Faculté de Médecine Université de la Méditerranée, Assistance Publique Hopitaux de Marseille, Marseille France
    Rev Mal Respir 23:4S17-4S26. 2006
    ..Bronchoscopy is frequently practised by respiratory physicians, particularly when there is a suspicion of lung cancer. However, few guidelines are available and practice varies widely...
  28. ncbi [Prognostic indicators in stage I non-small cell lung cancer]
    F Barlesi
    Departement des Maladies Respiratoires, Universite de la Mediterrannee, Hopitaux de Marseille, France
    Rev Mal Respir 21:93-103. 2004
    ..Better knowledge of prognostic factors could perhaps define which patient populations should be targeted with such treatments...
  29. ncbi [Use of 153Sm-EDTMP to relieve pain from bone metastasis in lung cancer]
    H Ratsimanohatra
    Service des Maladies Respiratoires, Hôpital général de Befelatanana, CHU Antananarivo, Madagascar
    Rev Mal Respir 22:317-20. 2005
    ..Management is based on pharmacologicalmethods (steroids, morphine, and pamidronate) and radiotherapy. However, other treatments have been developed including the systemic radiopharmaceutical 153Sm-EDTMP...
  30. ncbi Talcage by medical thoracoscopy for primary spontaneous pneumothorax is more cost-effective than drainage: a randomised study
    J M Tschopp
    Centre valaisan de pneumologie, Montana, Switzerland
    Eur Respir J 20:1003-9. 2002
    ....
  31. ncbi [Malignant pleural mesothelioma: role of excisional surgery]
    R Giudicelli
    Chirurgie Thoracique, CHU, Marseille
    Rev Mal Respir 23:11S51-5. 2006
  32. ncbi [Which criteria for the anatomopathologic diagnosis of malignant pleural mesothelioma?]
    F Galateau-Salle
    Groupe Mesopath, CHU Caen
    Rev Mal Respir 23:11S37-44. 2006
  33. ncbi [Which diagnostic criteria for malignant pleural mesothelioma (MPM)?]
    P Astoul
    CHU Marseille, France
    Rev Mal Respir 23:11S29-35. 2006
  34. ncbi [How to assess asbestos exposure and identify a population at risk?]
    J C Pairon
    Service de pneumologie et pathologie professionnelle, CHI Creteil, et INSERM E03 37, Faculte de Medecine, Creteil, France
    Rev Mal Respir 23:11S9-27. 2006
  35. ncbi [Hypersensitivity to carboplatin. An effect of generic drugs?]
    Y Gernez
    Faculte de Medecine, Universite de la Mediterranee, Service de pneumologie allergologie Hôpital Sainte Marguerite Marseille, France
    Rev Mal Respir 23:269-72. 2006
    ..Carboplatin is a chemotherapeutic agent used frequently in thoracic medicine on account of its relatively good tolerance. Nevertheless hypersensitivity reactions have been described...
  36. ncbi [Reducing the risks associated with bronchoscopy: a call for a standardisation of practice]
    P Astoul
    Rev Mal Respir 20:319-22. 2003
  37. ncbi Management of spontaneous pneumothorax: state of the art
    J M Tschopp
    Valais Pneumology Centre, Crans Montana, Switzerland
    Eur Respir J 28:637-50. 2006
    ..Moreover, all of these new techniques should be better standardised to permit comparison in randomised controlled studies...